As in previous years, the consensus group to consider the use of biological agents in the
treatment of rheumatic diseases met during the 13th Annual Workshop on Advances in …

Background Patients treated with methotrexate for rheumatoid arthritis often improve but
continue to have active disease. This study was undertaken to determine whether the …

Background Increases in lipid levels and cancers with tofacitinib prompted a trial of major
adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis …

Background Etanercept, which blocks the action of tumor necrosis factor, reduces disease
activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease …

Background Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the
pathogenesis of rheumatoid arthritis, and antagonism of TNF may reduce the activity of the …

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]: Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Objective To examine the efficacy and safety of different rituximab doses plus methotrexate
(MTX), with or without glucocorticoids, in patients with active rheumatoid arthritis (RA) …

Objective To compare the clinical and radiographic outcomes in patients with rheumatoid
arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 …

Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid …

Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated for the treatment of rheumatoid arthritis. Methods In this 12-month, phase 3 trial …